Browse News
Filter News
Found 16 articles
-
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
-
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
1/24/2024
Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the achievement of two compelling new data sets with its next generation bifunctional degraders demonstrating in vivo efficacy and the ability to target and degrade proteins in the central nervous system (CNS).
-
Camena Bioscience Appoints Dr Nicola Thompson as Chair of the Board
12/6/2023
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.
-
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
9/26/2023
Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone.
-
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb
5/4/2023
Amphista Therapeutics today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.
-
Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer
5/2/2023
Amphista Therapeutics announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer.
-
Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases
12/13/2022
Amphista Therapeutics, a leader in next generation targeted protein degradation approaches, announced a Series B extension investment by the Dementia Discovery Fund.
-
Protein Sequencing Market Size to Hit Around USD 1.91 BN by 2030
10/26/2022
The global protein sequencing market was surpassed at USD 1.4 billion in 2021 and is expected to hit around USD 1.91 billion by 2030, growing at a CAGR of 3.51% from 2022 to 2030.
-
Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases
10/25/2022
Adrestia Therapeutics announced the appointment of Dr James Osborne as Head of Chemistry and the initiation of a multi-target partnership with Proteros biostructures GmbH to accelerate the discovery of first-in-class candidate drugs for intractable diseases.
-
Amgen opened a new research and development site in San Francisco Bay, while Enzo Biochem opened a 100,000 square foot laboratory and research facility in New York
-
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.
-
Bristol Myers Squibb announced it is extending and expanding its strategic partnership with Evotec in targeted protein degradation, marking its second protein degradation deal this month.
-
Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
-
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
5/4/2022
Amphista and Merck will collaborate to leverage Amphista's proprietary Eclipsys™ TPD platform and generate novel protein degrading therapeutics in oncology and immunology.
-
Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
5/4/2022
Amphista and Bristol Myers Squibb to collaborate and leverage Amphista's proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics.
-
Amphista Therapeutics Appoints Dr Martin Pass as CDO
12/6/2021
Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Martin Pass, as Chief Development Officer (CDO).